GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 10,559 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) CEO Katherine Stueland sold 10,559 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89. Following the transaction, the chief executive officer now directly owns 14,865 shares in the company, valued at $1,437,594.15. This trade represents a 41.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

  • On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total value of $96,416.32.
  • On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
  • On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $130,041.36.
  • On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60.
  • On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $94.46 on Tuesday. The firm has a market cap of $2.65 billion, a P/E ratio of -48.19 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 1-year low of $7.72 and a 1-year high of $115.60. The business’s 50 day moving average is $84.69 and its 200-day moving average is $70.37.

GeneDx (NASDAQ:WGSGet Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. Equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

Check Out Our Latest Analysis on WGS

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC increased its stake in shares of GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after acquiring an additional 316 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx during the 4th quarter valued at $28,000. Lazard Asset Management LLC acquired a new position in GeneDx during the 4th quarter worth about $35,000. Finally, Comerica Bank acquired a new position in GeneDx during the 4th quarter worth about $50,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Recommended Stories

Insider Buying and Selling by Quarter for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.